Background. Individuals infected with human immunodeficiency virus (HIV) are at increased risk for severe influenza, yet immune responses to standard-dose intramuscular (IM) influenza vaccine are suboptimal in this population. Intradermal (ID) delivery of influenza vaccine might improve immune response through enhanced stimulation of dendritic cells.
An estimated 35 million people live with human immunodeficiency virus (HIV) infection globally, with a disproportionate number living in lower-income countries [1] . Influenza is a common cause of respiratory illness among persons living with HIV/ AIDS (PLWHA) [2] , and advanced HIV is associated with higher rates of influenza hospitalization and death [3] [4] [5] [6] . Influenza vaccination is the most effective method to prevent influenza [7] and is recommended for PLWHA by the World Health Organization [8] . While influenza vaccination is safe and moderately effective among PLWHA [7, [9] [10] [11] [12] , antibody responses to intramuscular (IM) vaccine may be impaired [13] [14] [15] , with the poorest response in those with a CD4 count <200 cells/µL [15] [16] [17] . Furthermore, the durability of antibody responses to influenza vaccine may be reduced in PLWHA [18] . Thus, influenza vaccines that provide more effective and durable protection are needed for PLWHA, especially those with low CD4 cell counts.
In 2010, an intradermal (ID) influenza vaccine was licensed for use in several countries. ID delivery is thought to be more efficient than IM delivery because of the abundance of immunostimulatory cells in the dermis that act as potent antigen presenting cells [19] . Several studies have found no difference in antibody responses when comparing reduced-dose ID (3 µg hemagglutinin [HA] [20, 21] or 9 µg HA [22] ) with standard-dose IM vaccines (15 µg HA) among PLWHA. Although some studies have demonstrated superior immunogenicity of equivalent-dose ID vs IM vaccine in older adults [19, 23, 24] , no comparable studies have been conducted among PLWHA.
In Thailand, HIV prevalence is estimated at 1.1% among the general population [25] and is substantially higher (>20%) in certain populations such as men who have sex with men (MSM) [26] . Influenza viruses circulate perennially in Thailand, resulting in year-round opportunities for influenza transmission [27] . Thailand's Advisory Committee on Immunization Practices recommends influenza vaccine for 8 high-risk groups, including persons with chronic diseases [28] . To determine whether ID vaccine may improve antibody responses in PLWHA, we conducted a clinical trial comparing the immunogenicity of equivalent-dose ID and IM influenza vaccines among HIV-infected MSM in Bangkok, Thailand.
METHODS

Study Design, Objectives, and Outcomes
This randomized, double-blind, controlled trial was conducted during 2011-2013 at the Silom Community Clinic (SCC), Bangkok, Thailand. SCC provides sexually transmitted infection voluntary testing and counseling services for MSM and is also the site of the Bangkok MSM Cohort Study (BMCS), a study to estimate HIV infection incidence among Thai MSM [26] .
The primary study outcome was seroconversion at 1 month postvaccination based on serum hemagglutination inhibition (HI) antibody titers against each vaccine strain [29] . The secondary outcomes were seroconversion, geometric mean titer (GMT), and seroprotection, all measured by HI against each vaccine strain at 6 and 12 months postvaccination and GMT and seroprotection at 1 month postvaccination.
Enrollment, Randomization, and Blinding
Participants were recruited from SCC and other HIV clinics in Bangkok. Eligible persons were of Thai nationality, MSM, HIV infected, and 18-60 years old. Written informed consent was obtained from all eligible persons. HIV-uninfected MSM were enrolled as a laboratory control group (Supplementary Data).
At enrollment, all non-BMCS participants received confirmatory HIV testing (Supplementary Data). Participants were also tested for CD4 cell count and plasma HIV RNA load at enrollment and 1 month postvaccination.
Participants were randomly assigned in a 1:1 ratio to receive ID or IM vaccine (Supplementary Data). Randomization was initially stratified by CD4 count (≥200 or <200 cells/µL). After the first 8 months, enrollment of participants with a CD4 count <200 cells/µL lagged substantially, so stratification by CD4 cell count was dropped to ensure adequate enrollment to evaluate primary study objectives.
While study nurses were aware of vaccine assignments, all other study investigators were blinded to vaccine assignment until the conclusion of data analysis. Study participants were able to view the vaccine as they received it but were not specifically told to which vaccine group they had been assigned.
Vaccine and Vaccine Product
The IM (VAXIGRIP) and ID vaccines (Intanza/IDflu) are both inactivated, split-virion, trivalent influenza vaccines. 
Influenza Serologic Testing
Participants had 10 mL of venous blood drawn prior to vaccination and at 1, 6, and 12 months postvaccination. Serum was tested by HI using guinea pig erythrocytes for antibody responses to vaccine strains. We performed 2-fold serial dilutions starting at 1:10 and ending at 1:1280; any sample positive at 1:1280 was repeated to the end dilution. Serum from all time points was tested on the same plate, and laboratory staff was blinded to randomization group and time point. Specimens were tested at the Armed Forces Research Institute of Medical Science in Bangkok, Thailand, using the standard World Health Organization protocol [30, 31] .
Safety Monitoring
Participants recorded solicited and unsolicited adverse events (AEs) daily for 7 days postvaccination. AE severity was assessed using a 4-point scale [29] . AE relatedness was characterized as associated (temporally related to administration of vaccine and not explained by any other etiology) or not associated. Safety oversight involving review of all AEs was provided by a physician safety monitor who was not involved in the conduct of the study. After the first 10% of participants were enrolled, the safety monitor performed an interim analysis to determine whether stopping criteria were met (Supplementary Data).
Statistical Analysis
Seroconversion was defined as either a day 0 titer <1:10 and a day 30 titer ≥1:40 or a day 0 titer >1:10 and >4-fold rise at 1 month in serum HI titers against each vaccine strain. Seroprotection was defined as ≥1:40 antibody titer against each vaccine strain at 1 month [32] . Mean GMTs were calculated prior to vaccination (day 0) and at 1 month postvaccination (day 30); GMT ratios were calculated by dividing GMT at day 30 by GMT at day 0. To allow for calculation of GMTs, a titer of 1:5 was arbitrarily assigned to participants with undetectable (<1:10) HI antibody responses to vaccine. Missing HI titers at any visit were also assigned a titer of 1:5. We determined the percentage with 95% confidence intervals (CIs) of individuals who achieved seroconversion or seroprotection at each time point.
Frequencies of seroconversion and seroprotection at 1 month were compared between study arms using χ 2 or Fisher exact tests. GMTs were compared between study arms using Wilcoxon rank-sum test or Student t test. All analyses were conducted as intention-to-treat. A sensitivity analysis was performed using the "worst-case" analysis approach in which all missing outcome data were assumed to equal an undetectable immune response. Data analysts conducted all preliminary analyses with a dummy vaccine variable and were unblinded only in the final stages of analysis. All tests were 2-tailed with a level of significance of .05. In a prespecified subgroup analysis, logistic regression was used to assess for interaction between vaccine type and CD4 cell count. Analyses were conducted using SAS software, version 9.2 (SAS Institute, Cary, North Carolina).
Sample Size
Assuming a type 1 error of 5% and type 2 error of 20%, 182 HIV-infected participants per arm would be required to demonstrate a 15% difference in the proportion of participants with seroconversion at 1 month to ID vs IM vaccine. The estimated sample size was increased to 200 participants per arm to account for 10% loss to follow-up. This study was approved by the Ethical Review Committee for Research in Human Subjects of the Thai MOPH, and the Institutional Review Board of the Centers for Disease Control and Prevention, Atlanta, Georgia. Study findings are reported in accordance with the recommendations of the CONSORT (Consolidated Standards of Reporting Trials) statement. Figure 1 . Enrollment and follow-up of study participants. *For intramuscular vaccine: 1 person did not complete the 1-month visit and 14 completed it outside of the acceptable window period; 11 persons did not complete the 6-month visit and 7 completed it outside the acceptable window period; 13 people did not complete the 12-month visit and 10 completed it outside the acceptable window period. **For intradermal vaccine: 1 person did not complete the 1-month visit and 10 completed it outside of the acceptable window period; 6 persons did not complete the 6-month visit and 5 completed it outside the acceptable window period; 11 people did not complete the 12-month visit and 7 completed it outside the acceptable window period. Abbreviation: HIV, human immunodeficiency virus.
RESULTS
Study Enrollment
We enrolled and vaccinated 400 HIV-infected MSM (200 received IM and 200 ID vaccine; Figure 1 ). Among the 200 IM vaccine recipients, 185 (93%), 182 (91%), and 177 (89%), and among the 200 ID vaccine recipients, 189 (95%), 189 (95%), and 182 (91%), returned within the prespecified periods for their 1, 6 , and 12 month follow-up visits, respectively (Figure 1 ).
Baseline Characteristics
The median age of IM and ID vaccine recipients was 29 and 30 years, respectively (Table 1) (Table 2) . A similar proportion of participants in each group experienced systemic AEs. The most common systemic reactions included myalgia, malaise, and headache. Grade 3 or higher systemic AEs were rare, occurring in ≤4% of participants in either vaccine group.
Antibody Responses at 1 Month Postvaccination
Antibody responses 1 month postvaccination did not significantly differ between vaccine groups (Table 3 ). Prior to vaccination, seroprotection to all 3 vaccine strains was 0% in both vaccine groups, and seroprotection to at least 1 of the 3 vaccine strains was 22% among IM and 19% among ID vaccine recipients (Table 3) vaccine strains, respectively, at 1 month postvaccination. Among participants with a CD4 count <200 cells/µL, 3 of 45 (7%) and 19 of 45 (42%) IM vaccine recipients and 2 of 40 (5%) and 11 of 40 (28%) ID vaccine recipients seroconverted to all or at least 1 of the 3 vaccine strains, respectively, at 1 month postvaccination (Figure 2A ). For seroprotection, among participants with a CD4 count ≥200 cells/µL, 35 of 155 (23%) and 128 of 155 (83%) IM vaccine recipients and 40 of 160 (25%) and 135 of 160 (84%) ID vaccine recipients had seroprotection to all or at least 1 of the 3 vaccine strains, respectively, at 1 month postvaccination. Among participants with a CD4 count <200 cells/µL, 4 of 45 (9%) and 25 of 45 (56%) IM vaccine recipients and 3 of 40 (8%) and 13 of 40 (33%) ID vaccine recipients had seroprotection to all or at least 1 of the 3 vaccine strains, respectively, at 1 month postvaccination ( Figure 2B ). In our prespecified subanalysis, we found a significant interaction term (P = .046) between CD4 cell count and vaccine arm for seroprotection but not seroconversion to any of the three viruses.
Antibody Responses at 6 and 12 Months Postvaccination
The proportion of participants with seroprotection to all (Figure 3A) or at least 1 ( Figure 3B ) of the 3 vaccine strains was lower at 6 months vs 1 month postvaccination for both vaccine groups. Seroprotection at 6 and 12 months was similar for both vaccine groups. Similar to the findings for seroprotection, seroconversion to all (Supplementary Figure 1A) or at least 1 (Supplementary Figure 1B ) of the 3 vaccine strains was lower at 6 months vs 1 month postvaccination, and similar at 6 months vs 12 months, for both vaccine groups. GMTs to each of the 3 virus strains did not significantly differ between vaccine groups at 1, 6, and 12 months postvaccination ( Supplementary Figures 2A, 2B, 2C) . 
DISCUSSION
In our population of HIV-infected MSM in Bangkok, standarddose ID influenza vaccine was safe but was not more immunogenic at 1 month postvaccination compared with standard-dose IM vaccine. Seroconversion was low for both vaccine groups and ranged from 14% to all vaccine strains to 77% to at least 1 vaccine strain. Antibody responses were reduced at 6 and 12 months compared with 1 month postvaccination and were similar in both vaccine groups. Vaccine responses may have been modified by immune status. Among participants with a CD4 count <200 cells/µL, seroconversion and seroprotection was higher at 1 month among IM compared to ID vaccine recipients, although only the difference in seroprotection was statistically significant. Overall, regardless of vaccine group, antibody responses were higher for participants with a CD4 count >200 cells/µL. While influenza vaccination is recommended for all PLWHA, the efficacy of standard-dose IM vaccine is suboptimal [9, 10, 12] . Because vaccine efficacy studies with symptomatic influenza as the endpoint require substantial resources, serologic responses to vaccine are often used as a proxy for efficacy. Many studies have found suboptimal immunogenicity of influenza vaccine among PLWHA, consistent with our findings [13] [14] [15] [16] [17] . Strategies for boosting antibody responses to influenza vaccine, including use of higher-dose vaccines [33, 34] , multidose regimens [33, 35, 36] , and vaccine adjuvants [36] [37] [38] [39] have demonstrated mixed results.
ID delivery of influenza vaccine is a promising approach to increasing immunogenicity in older adults and immunocompromised populations [40] . Studies among non-HIV-infected older adults, who may have decreased immune function, have found standard-dose ID vaccine to be more immunogenic than conventional IM vaccine [23, 24] . However, few studies in PLWHA have examined antibody responses to vaccine delivered by an ID vs IM route, and none have compared standarddose ID to standard-dose IM vaccine. Studies comparing lowdose ID to standard-dose IM vaccine have found noninferiority of low-dose ID vaccine [20] [21] [22] . Given previous findings, it was somewhat surprising that ID vaccine did not elicit higher HI responses 1 month postvaccination in our study. One contributing factor may be that the majority of participants had detectable HIV RNA loads despite having CD4 counts >200 cells/µL. HIV virologic suppression has been associated with increased seroconversion rates postvaccination [41, 42] . Our study was not designed to examine associations between viral suppression and antibody responses to vaccination.
Although overall antibody responses to both vaccine types at 1 month were relatively low, responses were higher among those with CD4 >200 cells/µL, consistent with findings from multiple other studies [15] [16] [17] . Although our study was not powered to look at antibody responses to vaccine by CD4 cell count, we did observe a trend toward lower antibody responses as measured by seroconversion and seroprotection at 1 month following ID vs IM vaccination among those with CD4 counts <200 cells/µL. While there was an initial drop in seroconversion and seroprotection between 1 and 6 months postvaccination, antibody responses generally remained stable between 6 and 12 months. Data on antibody persistence in PLWHA after influenza vaccination are limited. Similar to our findings, Crum-Cianflone and colleagues found a decline in seroprotection after a single dose of monovalent 2009 influenza A(H1N1) vaccine at 6 months postvaccination [18] . In countries such as Thailand, where influenza circulates year-round, additional strategies are needed to boost the durability of immune responses to influenza vaccine.
As has been previously described [19] , ID vaccination did result in a higher number of low-grade injection-site reactions compared with IM vaccination. However, neither vaccine elicited high-grade local reactions, and both had similar systemic AE profiles. Although the increase in local injection-site reactions is a potential deterrent to widespread use of ID vaccine, studies have shown that ID vaccine is highly acceptable because of the use of smaller needles with a decreased depth of penetration and decreased pain at the time of injection [43, 44] . Cost may also be a potential deterrent in low-and middle-income countries, as newer technologies for delivery of ID vaccine, including microinjection systems and disposable-syringe jet injectors, are more expensive than traditional IM delivery. Both cost and AE profiles will need to be considered as ID vaccine strategies are investigated for use in PLWHA in low-to middle-income countries.
Several limitations to this study should be noted. Immunogenicity may not be directly translatable to clinical disease prevention strategies. However, a recent randomized controlled trial by Madhi and colleagues of trivalent inactivated influenza vaccine vs placebo among PLWHA found higher clinical efficacy against confirmed influenza illness than predicted by corresponding immunologic outcomes [9] , supporting the use of antibodies as a reasonable proxy for clinical vaccine efficacy. Second, given that the Thai MSM included in this study were relatively homogenous with respect to age and HIV indicators, our ability to generalize these results to other populations may be limited. Third, while vaccine response may have been modified by CD4 cell count, our study was not powered to look at antibody responses stratified by CD4 count. A major strength of this study was the high retention rate, which allowed us to evaluate our primary outcome of seroconversion at 1 month postvaccination as well as secondary seroconversion and seroprotection outcomes at 6 and 12 months postvaccination.
Our data support the safety of ID influenza vaccine among PLWHA and also demonstrate comparable immunogenicity of standard-dose ID and IM vaccine. As the majority of participants in our study had relatively preserved immune function, additional studies are needed to specifically examine the immunogenicity of ID vaccine among persons with CD4 counts <200 cells/µL.
Although ongoing strategies are needed to optimize immune responses to influenza vaccine among PLWHA, currently available vaccines are still moderately efficacious in reducing the risk of influenza illness and should be administered yearly in this vulnerable population.
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